Adicet Bio, Inc. (ACET) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ACET currently has 9.35M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 85.19% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 9.3M shares outstanding |
9.3M | 0 |
| Mar 12, 2026 |
S-3 filing: Adicet Bio, Inc. may issue up to $250,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units, in any combination, together or separately, in one or more offerings. |
9.6M | 0 |
| Mar 12, 2026 |
10-K filing | 9.6M shares outstanding |
9.6M | 0 |
| Dec 30, 2025 |
Stock Split
8-K filing: Stock split 1-for-16 | Outstanding: 153,255,581 → 9,578,473 |
9.6M | 0 |
| Nov 05, 2025 |
10-Q filing | 153.3M shares outstanding |
150M | 0 |
| Oct 07, 2025 |
8-K filing: Adicet Bio, Inc. entered into an Underwriting Agreement for an underwritten registered direct offering of 70,001,000 shares of common stock and pre-funded warrants to purchase 10,000,000 shares of common stock. ($80.0M proceeds) |
91M | 52M |
| Aug 07, 2025 |
10-Q filing | 91.1M shares outstanding |
91M | 52M |
| May 06, 2025 |
10-Q filing | 82.7M shares outstanding |
83M | 61M |
| Mar 06, 2025 |
10-K filing | 87.9M shares outstanding |
88M | 56M |
| Mar 06, 2025 |
S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, and debt securities for a total aggregate amount of $250,000,000. They also have an active ATM offering. |
83M | 61M |
| Nov 06, 2024 |
10-Q filing | 82.4M shares outstanding |
82M | 0 |
| Aug 13, 2024 |
10-Q filing | 90.6M shares outstanding |
91M | 0 |
| May 14, 2024 |
10-Q filing | 79.1M shares outstanding |
79M | 0 |
| Mar 19, 2024 |
10-K filing | 82.2M shares outstanding |
82M | 0 |
| Jan 24, 2024 |
8-K filing: Adicet Bio, Inc. completed a public offering of 27,054,667 shares of common stock and pre-funded warrants to purchase 8,445,333 shares, with the underwriters exercising their option to purchase an additional 5,325,000 shares of common stock, resulting in estimated net proceeds of approximately $91.8 million. ($19.3M proceeds) |
43M | 0 |
| Nov 08, 2023 |
10-Q filing | 43.0M shares outstanding |
43M | 0 |
| Aug 09, 2023 |
10-Q filing | 43.0M shares outstanding |
43M | 0 |
| May 09, 2023 |
10-Q filing | 43.0M shares outstanding |
43M | 0 |
| Mar 15, 2023 |
10-K filing | 41.1M shares outstanding |
41M | 0 |
| Nov 08, 2022 |
10-Q filing | 41.6M shares outstanding |
42M | 0 |
| Aug 10, 2022 |
10-Q filing | 40.1M shares outstanding |
40M | 0 |
| May 12, 2022 |
10-Q filing | 39.8M shares outstanding |
40M | 0 |
| Mar 16, 2022 |
S-3/A filing: This is an S-3/A filing to include the hyperlinks of Exhibits 5.1 and 23.1 in the Exhibit Index. |
40M | 0 |
| Mar 15, 2022 |
S-3 filing: The company may from time to time issue up to $500,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units. |
32M | 0 |
| Mar 15, 2022 |
10-K filing | 39.9M shares outstanding |
40M | 0 |
| Dec 10, 2021 |
8-K filing: Adicet Bio, Inc. completed a public offering of 6,250,000 shares of common stock at $14.00 per share, with the underwriters exercising their option to purchase an additional 937,500 shares, resulting in net proceeds of approximately $94.1 million. ($0.0M proceeds) |
32M | 0 |
| Nov 10, 2021 |
10-Q filing | 32.0M shares outstanding |
32M | 0 |
| Aug 12, 2021 |
10-Q filing | 31.8M shares outstanding |
32M | 0 |
| May 17, 2021 |
10-Q filing | 31.8M shares outstanding |
32M | 0 |
| May 13, 2021 |
S-3 filing: This S-3 filing registers 1,153,840 shares of common stock for resale by selling shareholders. |
32M | 0 |
| Mar 12, 2021 |
S-3 filing: The filing is an S-3 form for a shelf offering of up to $300,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units. It also includes an at-the-market offering of common stock with an aggregate offering price of up to $75,000,000. |
20M | 5M |
| Mar 12, 2021 |
10-K filing | 31.8M shares outstanding |
32M | 0 |
| Nov 05, 2020 |
10-Q filing | 19.6M shares outstanding |
20M | 0 |
| Jul 30, 2020 |
10-Q filing | 36.5M shares outstanding |
36M | 0 |
| May 07, 2020 |
10-Q filing | 36.4M shares outstanding |
36M | 0 |
| Mar 12, 2020 |
10-K filing | 36.4M shares outstanding |
36M | 0 |